- Home
- CCB vs AGIO Comparison
CCB vs AGIO Comparison
Compare CCB & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCB
- AGIO
- Stock Information
- Founded
- CCB 1997
- AGIO 2007
- Country
- CCB United States
- AGIO United States
- Employees
- CCB N/A
- AGIO N/A
- Industry
- CCB Major Banks
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- CCB Finance
- AGIO Health Care
- Exchange
- CCB Nasdaq
- AGIO Nasdaq
- Market Cap
- CCB 1.3B
- AGIO 1.4B
- IPO Year
- CCB 2018
- AGIO 2013
- Fundamental
- Price
- CCB $86.04
- AGIO $34.41
- Analyst Decision
- CCB Strong Buy
- AGIO Buy
- Analyst Count
- CCB 3
- AGIO 6
- Target Price
- CCB $103.33
- AGIO $58.60
- AVG Volume (30 Days)
- CCB 82.2K
- AGIO 650.0K
- Earning Date
- CCB 07-28-2025
- AGIO 07-31-2025
- Dividend Yield
- CCB N/A
- AGIO N/A
- EPS Growth
- CCB 17.53
- AGIO N/A
- EPS
- CCB 3.36
- AGIO 11.45
- Revenue
- CCB $322,160,000.00
- AGIO $37,035,000.00
- Revenue This Year
- CCB $109.11
- AGIO $22.30
- Revenue Next Year
- CCB $36.30
- AGIO $219.19
- P/E Ratio
- CCB $25.60
- AGIO $3.00
- Revenue Growth
- CCB 25.44
- AGIO 25.96
- 52 Week Low
- CCB $43.01
- AGIO $23.42
- 52 Week High
- CCB $102.25
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- CCB 50.04
- AGIO 59.47
- Support Level
- CCB $81.00
- AGIO $33.62
- Resistance Level
- CCB $92.63
- AGIO $35.82
- Average True Range (ATR)
- CCB 2.68
- AGIO 1.38
- MACD
- CCB -0.51
- AGIO 0.03
- Stochastic Oscillator
- CCB 43.35
- AGIO 52.52
About CCB Coastal Financial Corporation
Coastal Financial Corp is a financial service provider. The company provides banking products and services to consumers and small to medium-sized businesses. Its business is conducted through three reportable segments: The community bank, CCBX, and treasury & administration. The primary focus of the community bank is on providing a wide range of banking products and services to consumers and small to medium-sized businesses in the broader Puget Sound region in the state of Washington and through the Internet and mobile banking applications.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.